---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-054273"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2026-08-06T20:03:51+00:00"
generated_at: "2026-08-06T20:05:27.120450+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics Q2 revenue $151M (+3% ex-settlements); raises FY2026 guidance to $610-630M

## Summary
- Revenue $151.0M, up 3% YoY excluding patent settlement revenue; gross margin 74% vs 72%.
- Operating loss $19.6M vs prior-year operating income $30.1M; net loss $17.9M vs net income $34.5M.
- Acquired Proteintech Genomics for protein detection; collaborations with Cleveland Clinic and Lausanne University Hospital.
- Raises FY2026 revenue guidance to $610-630M from $600-625M, representing 2-5% growth ex-settlements.
- Cash and marketable securities $552.0M as of June 30, 2026.

## SEC filing metadata
- accession: 0001628280-26-054273
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2026-08-06T20:03:51+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000162828026054273/0001628280-26-054273-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000162828026054273/txg-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-054273
- JSON: https://secwatch.observer/filing/0001628280-26-054273.json
- Plain text: https://secwatch.observer/filing/0001628280-26-054273.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.